European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC) are written by experts representing all disciplines involved in cancer care in Europe. They give patients, health professionals, managers and policymakers a guide to essential care. Here, the essential requirements to treat ovarian cancer patients are described. Ovarian cancer patients continue to have low cure rates with wide variation in treatment and care in Europe and beyond. They require complex treatment that should be carried out in specialised ovarian/gynaecological cancer centres by professionals with the appropriate expertise interacting in a multidisciplinary team. Such centralisation is still not well established in many European countries. A patient-centred pathway from diagnosis through treatment to survivorship, managed in dedicated centres, is key to achieving optimal care and a successful clinical outcome.
BiganzoliLCardosoF, et al. Essential Requirements for Quality Cancer Care (ERQCC). The requirements of a specialist breast centre. Breast2020; 51: 65-84.
McCluggageWG, et al. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol2015; 28: 1101–1122.
9.
SilvaEGLawsonBCRamalingamP, et al. Precursors in the ovarian stroma: another pathway to explain the origin of ovarian serous neoplasms. Hum Pathol2022; 127: 136-145.
10.
ForstnerRMeissnitzerMCunhaTM.Update on imaging of ovarian cancer. Curr Radiol Rep2016; 4: 31.
11.
Expert Panel on Women’s Imaging, KangSKReinholdC, et al. ACR appropriateness criteria staging and follow-up of ovarian cancer. J Am Coll Radiol2018; 15: S198–S207.
12.
JordanKAaproMKaasaS, et al. European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. Ann Oncol2018; 29: 36–43.
13.
SegevYSegevLSchmidtM, et al. Palliative care in ovarian carcinoma patients-a personalized approach of a team work: a review. Arch Gynecol Obstet2017; 296: 691–700.
14.
FotopoulouFConcinNPlanchampF, et al. Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update. Int J Gynecol Cancer2020; 30: 436-440.
15.
HinchcliffEWestin ShannonNHerzog ThomasJ. State of the science: Contemporary front-line treatment of advanced ovarian cancer. Gynecol Oncol2022; 166: 18-24.
16.
Delgado BoltonRCAideNCollettiPM, et al. EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment, and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA). Eur J Nucl Med Mol Imaging2021; 48: 3286–3302.
17.
Delgado BoltonRCCalapaquí TeránAKPelletO, et al. The search for new 2-[18F]FDG PET/CT imaging biomarkers in advanced ovarian cancer patients: focus on peritoneal staging for guiding precision medicine and management decisions. Clin Nucl Med2021; 46: 906-907.
18.
BoellaardRDelgado-BoltonROyenWJ, et al. European Association of Nuclear Medicine (EANM). FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging2015; 42: 328–354.
19.
StaffordLJuddFGibsonP, et al. Anxiety and depression symptoms in the 2 years following diagnosis of breast or gynaecologic cancer: prevalence, course and determinants of outcome. Supp Care Cancer2015; 23: 2215–2224.
20.
OwnbyKK.Use of the distress thermometer in clinical practice. J Adv Pract Oncol2019; 10: 175–179.
21.
TravadoLReisJCWatsonM, et al. Psychosocial oncology care resources in Europe: a study under the European Partnership on Action Against Cancer (EPAAC). Psychooncology2017; 26: 523–530.
JordanKAaproMKaasaS, et al. European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. Ann Oncol2018; 29: 36–43.
24.
SegevYSegevLSchmidtM, et al. Palliative care in ovarian carcinoma patients-a personalized approach of a team work: a review. Arch Gynecol Obstet2017; 296: 691–700.
25.
FerrellBRTemelJSTeminS, et al. Integration of palliative care into standard oncology care: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol2017; 35: 96–112.
26.
FalandryCPommeretFGladieffL, et al. Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study. Lancet Health Long2022; 3: e176-e185.
27.
BorsonSScanlanJMChenP, et al. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc2003; 51: 1451–1454.
28.
European Society of Oncology Pharmacy. Quality Standard for the Oncology Pharmacy Service (QuapoS 6), https://esop.li/quapos (2018, accessed 29 November 2024).
29.
AkaevIRahimiSOnifadeO, et al. Tumour versus germline BRCA testing in ovarian cancer: a single-site institution experience in the United Kingdom. Diagnostics (Basel)2021; 11: 547.
30.
LeeKSeifertBA, et al. Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels. Gen Med2019; 21: 1497-1506.
31.
BayraktarSArunB.BRCA mutation genetic testing implications in the United States. Breast2017; 31: 224–232.
32.
ReidFBhatlaNOzaAM, et al. The World Ovarian Cancer Coalition Every Woman Study: identifying challenges and opportunities to improve survival and quality of life. Int J Gynecol Cancer2021; 31: 238–244.
33.
KehrloesserS, et al. Analysing the attributes of Comprehensive Cancer Centres and Cancer Centres across Europe to identify key hallmarks. Mol Oncol2021; 15: 1277-1288.
LedermannJ.AMatias-GuiuXAmantF, et al. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol2024; 35: 248-266.
